Omeros Other Long-Term Assets 2010-2025 | OMER

Omeros other long-term assets from 2010 to 2025. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Omeros Annual Other Long-Term Assets
(Millions of US $)
2024 $125
2023 $140
2022 $124
2021 $141
2020 $1
2019 $1
2018 $1
2017 $6
2016 $6
2015 $11
2014 $1
2013 $1
2012 $1
2011 $0
2010 $0
2009 $0
Omeros Quarterly Other Long-Term Assets
(Millions of US $)
2025-03-31 $123
2024-12-31 $125
2024-09-30 $131
2024-06-30 $134
2024-03-31 $137
2023-12-31 $140
2023-09-30 $121
2023-06-30 $117
2023-03-31 $121
2022-12-31 $124
2022-09-30 $145
2022-06-30 $128
2022-03-31 $135
2021-12-31 $141
2021-09-30 $1
2021-06-30 $1
2021-03-31 $1
2020-12-31 $1
2020-09-30 $1
2020-06-30 $1
2020-03-31 $1
2019-12-31 $1
2019-09-30 $1
2019-06-30 $1
2019-03-31 $1
2018-12-31 $1
2018-09-30 $6
2018-06-30 $6
2018-03-31 $6
2017-12-31 $6
2017-09-30 $6
2017-06-30 $6
2017-03-31 $6
2016-12-31 $6
2016-09-30 $11
2016-06-30 $11
2016-03-31 $11
2015-12-31 $11
2015-09-30 $1
2015-06-30 $1
2015-03-31 $1
2014-12-31 $1
2014-09-30 $1
2014-06-30 $1
2014-03-31 $1
2013-12-31 $1
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31 $1
2012-09-30 $1
2012-06-30 $1
2012-03-31 $1
2011-12-31 $0
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $0
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31 $0
2009-09-30 $0
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.205B $0.000B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $239.054B 28.75
Boston Scientific (BSX) United States $154.291B 38.63
Stryker (SYK) United States $149.710B 31.30
EssilorLuxottica (ESLOY) France $128.407B 0.00
Medtronic (MDT) Ireland $110.260B 15.63
Lonza Group Ag (LZAGY) Switzerland $50.622B 0.00
Haleon (HLN) United Kingdom $47.216B 26.92
ResMed (RMD) United States $37.817B 28.40
Agilent Technologies (A) United States $33.696B 21.97
GE HealthCare Technologies (GEHC) United States $33.311B 15.81
Terumo (TRUMY) Japan $27.198B 35.33
Koninklijke Philips (PHG) Netherlands $23.033B 16.16
Insulet (PODD) United States $21.551B 84.59
Zimmer Biomet Holdings (ZBH) United States $18.358B 11.79
Baxter (BAX) United States $15.708B 11.73
Smith & Nephew SNATS (SNN) United Kingdom $13.095B 0.00
Demant (WILYY) Denmark $9.110B 0.00
Sunny Optical Technology (SNPTF) China $8.561B 0.00
Bio-Rad Laboratories (BIO) United States $6.558B 22.82
Lantheus Holdings (LNTH) United States $5.573B 14.06
Prestige Consumer Healthcare (PBH) United States $4.039B 18.04
Perrigo (PRGO) Ireland $3.660B 9.28
Haemonetics (HAE) United States $3.526B 16.06
Shandong Weigao Medical Polymer (SHWGF) China $3.459B 0.00
Envista Holdings (NVST) United States $3.280B 27.25
ICU Medical (ICUI) United States $3.251B 23.97
GN Store Nord (GNNDY) Denmark $2.346B 19.43
LeMaitre Vascular (LMAT) United States $1.910B 42.70
QuidelOrtho (QDEL) United States $1.901B 13.07
AtriCure (ATRC) United States $1.598B 0.00
Acuren (TIC) United States $1.263B 0.00
AdaptHealth (AHCO) United States $1.216B 12.34
Green Thumb Industries (GTBIF) United States $1.111B 25.00
Neogen (NEOG) United States $1.057B 13.53
BioLife Solutions (BLFS) United States $1.015B 0.00
Phibro Animal Health (PAHC) United States $1.003B 12.82
Kestra Medical Technologies (KMTS) United States $0.908B 0.00
InMode (INMD) Israel $0.898B 9.05
CeriBell (CBLL) United States $0.698B 0.00
Owens & Minor (OMI) United States $0.607B 5.04
Evolus (EOLS) United States $0.587B 0.00
Maravai LifeSciences Holdings (MRVI) United States $0.578B 0.00
Curaleaf Holdings (CURLF) Canada $0.557B 0.00
Valneva SE (VALN) France $0.468B 0.00
Capricor Therapeutics (CAPR) United States $0.459B 0.00
Surmodics (SRDX) United States $0.413B 0.00
Tilray Brands (TLRY) Canada $0.396B 0.00
VAREX IMAGING (VREX) United States $0.335B 12.32
SNDL (SNDL) Canada $0.321B 0.00
SEMPERIT AG HLD (SEIGY) Austria $0.301B 0.00
Sanuwave Health (SNWV) United States $0.281B 0.00
Viemed Healthcare (VMD) United States $0.276B 23.27
Cerus (CERS) United States $0.252B 0.00
Cresco Labs (CRLBF) United States $0.250B 0.00
ZimVie (ZIMV) United States $0.250B 11.34
Sanara MedTech (SMTI) United States $0.249B 0.00
Quanterix (QTRX) United States $0.241B 0.00
Brainsway (BWAY) Israel $0.233B 61.65
Biote (BTMD) United States $0.227B 6.37
Canopy Growth (CGC) Canada $0.226B 0.00
Aurora Cannabis (ACB) Canada $0.220B 65.33
OraSure Technologies (OSUR) United States $0.215B 0.00
TriSalus Life Sciences (TLSI) United States $0.197B 0.00
Utah Medical Products (UTMD) United States $0.181B 14.71
High Tide (HITI) Canada $0.178B 0.00
Organigram Global (OGI) Canada $0.177B 0.00
Verano Holdings (VRNOF) United States $0.175B 0.00
Exagen (XGN) United States $0.144B 0.00
Vireo Growth (VREOF) United States $0.138B 0.00
FitLife Brands (FTLF) United States $0.120B 14.81
Jin Medical (ZJYL) China $0.108B 0.00
Veru (VERU) United States $0.102B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.089B 0.00
Fonar (FONR) United States $0.088B 11.32
Quipt Home Medical (QIPT) United States $0.084B 0.00
MacroGenics (MGNX) United States $0.083B 0.00
TerrAscend (TSNDF) Canada $0.078B 0.00
Cytosorbents (CTSO) United States $0.075B 0.00
Zynex (ZYXI) United States $0.074B 0.00
Apyx Medical (APYX) United States $0.072B 0.00
InterCure (INCR) Israel $0.067B 0.00
Agape ATP (ATPC) $0.063B 0.00
Jushi Holdings (JUSHF) United States $0.061B 0.00
ImmuCell (ICCC) United States $0.055B 0.00
Nephros (NEPH) United States $0.045B 59.98
Modular Medical (MODD) United States $0.044B 0.00
United-Guardian (UG) United States $0.038B 13.25
Rockwell Medical (RMTI) United States $0.028B 0.00
Safety Shot (SHOT) United States $0.023B 0.00
Allurion Technologies (ALUR) United States $0.018B 0.00
INLIF (INLF) $0.016B 0.00
Flora Growth (FLGC) United States $0.015B 0.00
Cellectar Biosciences (CLRB) United States $0.014B 0.00
Meihua Medical Technologies (MHUA) China $0.014B 0.00
Trinity Biotech (TRIB) Ireland $0.014B 0.00
Senestech (SNES) United States $0.007B 0.00
Innovative Eyewear (LUCY) United States $0.007B 0.00
IM Cannabis (IMCC) Canada $0.006B 0.00
GlucoTrack (GCTK) United States $0.004B 0.00
Akanda (AKAN) Canada $0.002B 0.00
Sharps Technology (STSS) United States $0.000B 0.00
InVivo Therapeutics Holdings (NVIVQ) United States $0.000B 0.00